Latest Aleve PM Copy Could Have 180-Day Exclusivity From More Competition

US consumers currently don't have access to enough private label/store brand competition for Aleve PM (naproxen/diphenhydramine), FDA decides in granting Apotex its first OTC ANDA approval with Competitive Generic Therapy designation and eligibility for a type of exclusivity unlike any other previously allowed for OTCs.

Apotex exterior

More from Regulation

More from Policy & Regulation